Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations

Expert Review of Clinical Immunology

Volumn 10, Issue 12, 2014, Pages 1567-1579

  Grinyó, Josep M ^a   Petruzzelli, Stefano ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Efficacy; Kidney transplantation; LCP Tacro; Liver transplantation; MeltDose ; Once daily administration; Pharmacokinetics; Prolonged release formulation; Safety; Tacrolimus

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; DELAYED RELEASE FORMULATION; IMMUNOSUPPRESSIVE AGENT;

AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TREATMENT FAILURE; GRAFT FAILURE; HAND TREMOR; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; PARTICLE SIZE; QUALITY OF LIFE; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; DELAYED RELEASE FORMULATION; GRAFT REJECTION;

DELAYED-ACTION PREPARATIONS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; TACROLIMUS;

EID: 84911141429     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.983903     Document Type: Review

References (60)

1. Those 2012 data are based on the Global Observatory on Donation and Transplantation (GODT) data, produced by the WHO-ONT collaboration
2. Available from: http://optn.transplant.hrsa.gov/latestData/rptData.asp [Accessed 3 June 2014]
3. Available from: http://optn.transplant.hrsa.gov/latestData/rptData.asp Data as of June 27, 2014 [Accessed 2 July 2014]
4. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29
5. Colombo D, Ammirati E. Cyclosporine in transplantation - a history of converging timelines. J Biol Regul Homeost Agents 2011;25:493-504
6. Calne R. Cyclosporine as a milestone in immunosuppression. Transplant Proc 2004;36:13S-5S
7. Prograf, prescribing information. Astellas Pharma US, Inc; Northbrook, IL: 2013
8. Advagraf 0.5 mg, 1 mg, 3 mg and 5 mg tacrolimus extended release capsules. Product Monograph. Astellas Pharma Canada, Inc. Markham, ON. 2010; Northbrook, IL
9. ASTAGRAF XL - tacrolimus capsule, coated, extended release. Astellas Pharma US, Inc; Northbrook, IL: 2014)
10. Webster AC, Taylor RRS, Chapman JR, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005;19(4):CD003961
11. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/ SRTR 2012 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration; Rockville, MD: 2014
12. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-157
13. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM181006.pdf
14. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43:623-53
15. Provenzani A, Santeusanio A, Mathis E, et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol 2013;19:9156-73
16. Abouljoud MS, Kumar MSA, Brayman KL, et al. Neoral® rescue therapy in transplant patients with intolerance to tacrolimus. Clin Transplant 2002;16:168-72
17. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000;13:313-26
18. Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK 506. Transplant Proc 1991;23:3175-8
19. Hardinger KL, Hutcherson T, Preston D, et al. Influence of pill burden and drug cost on renal function after transplantation. Pharmacotherapy 2012;32:427-32
20. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
21. Tielen M, van Exel J, Laging M, et al. Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: a 2-year follow-up study. J Transplant 2014;2014:675301
22. Morrissey PE, Reinert S, Yango A, et al. Factors contributing to acute rejection in renal transplantation: the role of noncompliance. Transplant Proc 2005;37:2044-7
23. Vlaminck H, Maes B, Evers G, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant 2004;4:1509-13
24. Michelon T, Dominguez V, Losekan A, et al. Kidney graft failure due to noncompliance. Transplant Proc 1999;31:3031-2
25. Jarzembowski T, John E, Panaro F, et al. Impact of non-compliance on outcome after pediatric kidney transplantation: an analysis in racial subgroups. Pediatr Transplant 2004;8:367-71
26. Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004;77:769-76
27. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009;9:2505-13
28. Krämer BK, Charpentier B, Bäckman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 2010;10:2632-43
29. Silva HT, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007;7:595-608
30. Niioka T, Satoh S, Kagaya H, et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation 2012;94:1013-19
31. Rath T. Tacrolimus in transplant rejection. Expert Opin Pharmacother 2013;14:115-22
32. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75
33. MeltDose® Technology by the US Patent and Trademark Office. US7217431
34. Nigro V, Glicklich A, Weinberg J. Improved bioavailability of MELTDOSE once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24 hrs: a scintigraphic and pharmacokinetic evaluation [abstract B1034]. American Transplant Congress, 2013
35. Gaber AO, Alloway RR, Bodziak K, et al. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation 2013;96:191-7
36. Holm P, Thomassen JQ, Rasmussen SR. MeltDose® a one step industrial process for the manufacturing of solid dispersion. 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; 7th to 10th April 2008; CCIB, Barcelona, Spain
37. Buch P, Holm P, Thomassen JQ, et al. IVIVC for fenofibrate immediate release tablets using solubility and permeability as in vitro predictors for pharmacokinetics. J Pharm Sci 2010;99(10):4427-36
38. Advagraf. European public assessment report (EPAR). Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000712/human-med-000629.jsp&mid=WC0b01ac058001d124
39. Vicari-Christensen M, Repper S, Basile S, et al. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. Prog Transplant 2009;19:277-84
40. Available from: www.drugbank.ca/drugs/DB00864
41. Gavhanea YN, Yadavb AV. Loss of orally administered drugs in GI tract. Saudi Pharm J 2012;20:331-44
42. Thörn M, Finnström N, Lundgren S, et al. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005;60:54-60
43. Alloway RR, Eckhoff DE, Washburn WK, et al. Conversion from twice-daily tacrolimus capsules to once-daily extendedrelease tacrolimus (LCPT): phase II trial of stable liver transplant recipients. Liver Transpl 2014;20:564-75
44. EMEA. Note for guidance on modified release oral and transdermal dosage forms: section II (pharmacokinetic and clinical evaluation). European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products; London: 1999
45. Feng S, Chapman WC, DuBay D. A phase 2 randomized study of the pharmacokinetics, safety and efficacy of LCP-Tacro tablets once-a-day vs Prograf capsules twice-a-day in de novo liver transplants [abstract 709]. Presented at the 2012 American Transplant Congress; 2-6 June 2012; Boston, Massachusetts
46. Budde K, Bunnapradist S, Grinyo JM, et al. Once daily LCP-Tacro MeltDose® tacrolimus vs. twice daily tacrolimus in de novo kidney transplants: one-year results of Phase 3, double-blind, randomized trial. Am J Transplant 2014;In press
47. CellCept, (mycophenolate mofetil) summary of product characteristics (SPC, SmPC)
48. Myfortic, (mycophenolate acid) summary of product characteristics (SPC, SmPC)
49. Nigro V, Glicklich A, Weinberg J. Flexible dosing of once-daily LCP-Tacro tablets: morning vs. evening randomized crossover chronopharmacokinetic study. AST/ESOT Joint Meeting; 12-14 October 2012; Nice, France
50. Barraclough K, Isbel N, Johnson D, et al. Once-versus twice-daily tacrolimus. Drugs 2011;71:1561-77
51. Hougardy JM, Broeders N, Kianda M, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011;91:566-9
52. Gabardi S, Nigro V, Johnson J, et al. Evaluation of steady-state pharmacokinetic parameters of LCP-Tacro™ and Advagraf® in healthy volunteers using a systems dynamic model [abstract 2308787]. Poster presented at the European Society of Transplantation. Vienna, 2013
53. Bunnapradist S, Alloway R, West-Thielke P, et al. Lower treatment failures in blacks and older denovo and stable kidney transplant recipients treated with envarsus once-daily meltdose tablets vs. twice-daily prograf capsules: a pooled subgroup analysis of two phase 3 trials [abstract# 50]. World Transplant Congress (WTC); 26-31 July 2014; San Francisco, California
54. Alloway R, Mulgaonkar S, Ueda K, et al. A phase 2 randomized study of the pharmacokinetics, safety and efficacy of LCP-tacro tablets once-a-day vs prograf capsules twice-a-day in de novo kidney transplants. Am J Transplant 2011;11:355
55. Mulgaonkar S, Alloway RR. LCP-Tacro demonstrated significantly fewer dose adjustments: results of a phase 2 randomized study of lcp-tacro (meltdose once-daily prolonged release tacrolimus tablets) vs. prograf® capsules twice-a-day in de novo kidney transplant patients [abstract 51]. The European Society for Organ Transplantation (ESOT) and the American Society of Transplantation (AST); 17-19 October 2014; Madrid, Spain; 2014
56. Bunnapradist S, Ciechanowski K, West-Thielke P, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant 2013;13:760-9
57. Albano L, Banas B, Klempnauer JL, et al. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation 2013;96:897-903
58. Grinyo JM, Rostaing L, Budde K, et al. Rapid attainment of tacrolimus trough levels early post-transplant reduces risk of treatment failure in de novo kidney transplant patients: a covariate analysis of a phase 3 double-blind study [abstract #1571]. World Transplant Congress; 26-31 July 2014; San Francisco, CA; 2014
59. Paul LC. Overview of side effects of immunosuppressive therapy. Transplant Proc 2001;33:2089
60. Gedaly R, Steinberg SM, Langone A, et al. LCP-Tacro - associated improvement in tacrolimus - induced tremors is also associated with improvement in quality of life: results of a switching study of kidney transplant patients with tremor (strato). European Society for Transplantation (ESOT); 2013